Researchers Evaluate Controversial Treatment for Parkinson’s Disease Psychosis
Health & BehaviorIn the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson’s disease psychosis, researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system concluding that the new drug, pimavanserin (marketed as Nuplazid), did not pose a statistically significant greater risk of death.